Showing 51–75 of 184 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Ashish Kumar Prakash, Chinkita Agrawal, Nishant Gupta, Pinky Goyal, Anand Jaiswal
**BACKGROUND:** Therapeutic Drug Monitoring (TDM) helps in optimizing the dose which maximizes the therapeutic benefit and minimizes the toxicity. In pulmonary and extrapulmonary tuberculosis (PTB/EPTB), it allows the physician to take actions timely for antitubercular treatment …
Andrés Marco, Indiana Jesús Abdo, Neus Solé, Enrique Gil-Tubella, Isabel Barnés, et al.
…tical comparative appraisal against shorter rifamycin-based regimens. For this purpose, documents issued by the WHO and by major national and international guidelines and consensus statements have been reviewed. The review focuses particularly on screening, diagnosis, and treatme…
María Asunción Pérez-Jacoiste Asín, Francisco López-Medrano, José María Aguado
…ften undergo more intensive and prolonged immunosuppressive regimens compared to recipients of other organ transplants with lower immunogenicity. Additionally, the risk of donor-derived TB is notably higher in lung transplantation, underscoring the critical importance of thorough…
Ayman Elbehiry, Eman Marzouk, Husam M Edrees, Riyad AlShaqi, Abousree T Ellethy, et al.
…rapeutic innovations such as shorter multidrug-resistant TB regimens and host-directed therapies. Special emphasis is placed on the translational gap-highlighting barriers to real-world implementation such as cost, infrastructure, and policy fragmentation. While innovations like …
Anna Starshinova, Ekaterina Belyaeva, Olga Irtyuga, Giunai Sefiyeva, Lubov Mitrofanova, et al.
…s the development of individualized and effective treatment regimens, which are particularly critical for pregnant patients. Recommendations for managing tuberculosis in pregnant women after COVID-19 infection include measuring D-dimer levels, performing echocardiography, and con…
Rafael Laniado-Laborín
One-third of the world's population is infected with M. tuberculosis. It is from this vast pool of infected people where the new cases of active disease originate. Most of these cases of latent infection are found in low-income countries where national tuberculosis programs conce…
Rafael Laniado-Laborín
The treatment of susceptible tuberculosis has evolved in the last 70 years, from requiring the use of toxic drugs (PAS, streptomycin by parenteral route) for two years, to exclusively oral treatment, with a combination of more effective and less toxic medications for six months. …
Leeberk Raja Inbaraj, Bella Devaleenal Daniel, Chandrasekaran Padmapriyadarsini
Treatment outcomes of tuberculous meningitis (TBM), a disease with high mortality depends on early diagnosis and management. The global and regional burden of TBM and drug resistant TBM (DRTBM) are largely unknown. DRTBM is associated with poorer treatment outcomes. The wider use…
T Nkomo, Z Udwadia, D Vambe, A van Rie, S S Thi, et al.
…ew and repurposed drugs included in the all-oral shorter TB regimens recommended by WHO for the treatment of multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) are becoming increasingly common globally. When strains ofhave resistance to one or more of these drugs (bedaquilin…
Akanksha Sirohi, Yash Vardhan Trivedi, Tavishi Katoch, Benjamin Walters, Vasu Bansal, et al.
…ased guidelines and literature on TB diagnostics, treatment regimens, and latent TB infection (LTBI) management was conducted. Key public health challenges and interventions targeting socioeconomic disparities, stigma, and healthcare access among high-risk populations were analyz…
Lynn Sosa, Lloyd N. Friedman
This chapter discusses the guidance on options for treatment recommended by established national and international organizations. Generally, practitioners should follow the guidelines specified by the organization that represents the geographical location of the treatment facilit…
Matthew Smyth, Monica Diaz, Deanna Saylor
…d prognostic utility and clinical trials demonstrating that regimens of oral lipid nanocrystal formulation and a single dose of liposomal formulation of amphotericin B maintain clinical efficacy with improved side effect profiles. An ongoing clinical trial of ceftriaxone for trea…
Ravindra Kumar Garg
…rospinal fluid (CSF) tests. Standard pulmonary tuberculosis regimens are suboptimal for central nervous system involvement due to poor drug penetration and prolonged treatment. Emerging resistance, particularly to rifampicin and isoniazid, further complicates the management. **A…
Anca Ionela Fâcă, Denisa Ioana Udeanu, Andreea Letiția Arsene, Beatrice Mahler, Doina Drăgănescu, et al.
… Nowadays, pharmacologic approaches utilise polytherapeutic regimens that, although showing increased efficacy, prominently affect the nutritional status of patients and modify multiple metabolic pathways, thus influencing both the effectiveness of therapy and the patient outcome…
Mohd Shariq, Javaid Ahmad Sheikh, Farhan Ahmed, Anwar Alam, Seyed E. Hasnain, et al.
…ating drug-resistant TB and are incorporated into treatment regimens. The advantages of drug repurposing, including cost savings, reduced development timelines, and the potential to address the challenges posed by drug-resistant TB, make it a valuable tool in the global fight aga…
Na Tian, Hongqian Chu, Qi Li, Hong Sun, Jingfang Zhang, et al.
Current TB treatment regimens are hindered by drug resistance, numerous adverse effects, and long treatment durations, highlighting the need for 'me-better' treatment regimens. Host-directed therapy (HDT) has gained recognition as a promising approach in TB treatment. It allows t…
Georgies Mgode, Dickens Bwana, Christophe Cox, Shelly Batra, C. F. Richter, et al.
Tuberculosis (TB) caused by Mycobacterium tuberculosis kills over one million people yearly. TB diagnosis and treatment are complicated, and hence innovative diagnostic and treatment adherence monitoring tools are important. In this chapter, the application of innovative model of…
Simon Tiberi, Temi Lampejo, Alimuddin Zumla
Rifampicin-resistant Tuberculosis (RR-TB) and Multidrug resistant Tuberculosis (MDR-TB) are a current global health threat, and are characterised by high mortality, chronic sequelae, complexity and high cost. The drug resistant form of this infectious disease was globally respons…
Mange Ram Yadav, Dushyant V. Patel, Divya Teli, Hiral Shah
Tuberculosis (TB) remains a substantial challenge for public health globally, impacting millions of individuals around the world. Despite extensive efforts to control the disease, it continues to pose a major public health challenge, involving therapeutic implications for multi-d…
Mani Sharma, Sakshi Kansal
Tuberculosis is the second most fatal infectious disease after AIDS. It is caused by the mycobacterium tuberculosis. There are numerous factors responsible for the emergence of multi-drug resistance and extensively drug resistance cases of tuberculosis, which involves high pill b…
Federico Appetecchia, Mariangela Biava, Giovanna Poce
Tuberculosis is a leading cause of mortality and morbidity worldwide, claiming 1.2 million deaths (including 208 000 people with HIV) and 10 million new cases in 2019. Current treatment suffers from significant shortcomings such as length, dosage regimen, toxicity, and resistance…
Vaseem Anjum
Hansen’s disease is one of the most ancient diseases that is still prevalent in the world. The causative agent, Mycobacterium leprae (M. leprae) has a long incubation period, clinical features after infection are identified late and these acid fast bacilli cannot be cultured – ma…
Sonia Singh, Yogesh Murti, Nitin Agrawal
Tuberculosis is commonly called TB and considered to be the most contagious disease. This disease is caused by a causative agent known as Mycobacterium tuberculosis within the host body cells. Emergence incidence of XDR and MDR of tuberculosis are due to high dose intake and prol…
Shahista, Jappreet Kaur, Amit Kumar Singh, Vivek Kumar Garg
Drug-resistant tuberculosis (DR-TB) is described as tuberculosis that is not responding to one or more anti-TB medications. A person is diagnosed with DR-TB if they do not respond to regular TB treatment; then a more challenging treatment regimen and a longer treatment duration a…
Venkateswara Reddy Basu
Author Dr. Basu Venkateswara Reddy, Professor and Head, Department of Pharmaceutics, Sri.K.V.College of Pharmacy, Chikkaballapura, Karnataka, India Abstract The management of respiratory disorders is structured around algorithms that differentiate disease states and guide stepwis…